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Chronic Medication Use and 
Inflammatory Skin Diseases: The 
Power and Limitations of the Case–
Control Study
Robert S. Stern1
The potential of newly introduced medications to cause acute inflammatory skin 
diseases has long been recognized. Less well accepted and not often systemati-
cally studied is the role of long-term drug use in inflammatory skin diseases such as 
eczema. Hypothesis-driven case–control studies provide what is probably the most 
efficient but far from easy method to evaluate and quantify observations from case 
reports and case series that suggest a drug etiology for chronic skin diseases.
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In assessing this work, three ques-
tions come to mind. Are the findings 
from each approach used robust enough 
to suggest that chronic use of CCBs can 
cause “eczematous” eruptions in the 
“elderly”? How helpful are these findings 
for clinical practice? What further studies 
are warranted?
The authors have carefully built on 
their earlier observations to solve a small 
part of a vexing problem—are there 
reversible causes of otherwise unex-
plained chronic extensive eczematous 
eruptions in the “elderly”? In a prior ret-
rospective case series of older individuals 
with chronic eczema, Joly and colleagues 
found that older persons whose eczema 
was unexplained used more medicines 
than those whose “eczema” was attribut-
able to one of the “usual suspects” (Morin 
et al., 2002). These unexplained erup-
tions occurred more frequently on sun-
exposed areas, but seasonality was not 
noted. With this suggestive evidence that 
chronic use of drugs might explain some 
cases of eczema, Joly et al. designed a 
case–control study that prospectively 
ascertained cases of eczema among peo-
ple 60 years old and older.
Three of the top five “known” reasons 
for new-onset extensive eczema among 
candidate cases were infrequent diseases 
in the general population—lymphoma, 
scabies, and pemphigoid—suggesting 
that the study population is not likely to 
be representative of all elderly with new-
onset eczema but is more likely to rep-
resent those served by specialized uni-
versity-based clinics, which may affect 
the generalizability of these findings to 
patients seen in less specialized practice 
settings.
By itself, this case–control study pro-
vides good evidence (level of evidence 
2B) of a modest but significant associa-
tion between CCB use and new-onset 
eczema (odds ratio = 2.5). The authors 
attempt to bolster our confidence in the 
validity of these findings with “ecologi-
cal” (noncontrolled) studies, which they 
very reasonably title “ancillary studies.” 
In the retrospective analysis of a sepa-
rate population from the same principal 
center, they note that the withdrawal of 
CCBs was more likely to be followed by 
relief than withdrawal of other drugs that 
had been suspected as causes of chronic 
eczema eruptions. Case histories from 
the French “enhanced” spontaneous 
reporting system were supportive. Most 
of the small number of rechallenges were 
also positive, indicating that, at least for 
a small fraction of those for whom CCB 
use was suspected, the gold standard for 
“proving” drug etiology in the individual 
patients was fulfilled.
However, potential bias in selection 
of patients for reporting, dechallenge, 
and rechallenge, particularly in “spon-
taneous reporting systems,” makes inter-
pretation of these results difficult. In such 
systems, successes are more likely to be 
reported than failures. For example, in 
the pharmacovigilence data, 83% recov-
ered after stopping CCBs. Based on the 
data from the case control study, which is 
likely to be less subject to reporting bias 
than “spontaneous reports,” given the 
high proportion of elderly using CCBs 
Calcium channel blockers (CCBs) have 
long been recognized as causes of acute 
cutaneous eruptions and may exacer-
bate chronic skin conditions (Stern and 
Khalsa, 1989; Kitamura et al., 1993). In 
this issue of the Journal of Investigative 
Dermatology, Joly and colleagues have 
once again demonstrated the power, 
complexity, and limitations of three 
established approaches to determining 
the etiology of a specific skin condi-
tion that may be related to chronic use 
of medications: spontaneous reports, 
retrospective analysis of clinical experi-
ence (a case series), and a case–control 
study (Joly et al., 2007, this issue). As is 
appropriate, Joly et al. used observations 
from their institutions’ clinical experi-
ence to help frame the question for the 
case–control study that is the core of the 
findings presented in this issue of the 
JID. After establishing a clinically believ-
able association, the authors used data 
from a hypothesis-driven retrospective 
review of responses to drug withdrawal 
and rechallenge from their own cases as 
well as data from French pharmacovigi-
lance spontaneous reports to provide 
confirmatory evidence for the associa-
tion noted in the case series and case–
control study.
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and the relatively low relative risk of 
“unexplained” eczema associated with 
CCB use, we would have expected only 
about half of the cases of “unexplained” 
eczema among CCB users to be due to 
the drug, with the remaining half of such 
cases not related to CCB use.
Potential additional issues concerning 
the robustness of the finding are related to 
case definition, selection of controls, and 
possible informational bias. Although I 
have a mental picture of the eruption 
based on the data presented, I am not 
sure it is a correct one. For the results 
to be clinically useful and replicable, a 
clearer definition of “cases” with more 
information about the extent, distribu-
tion, morphology, and perhaps pathology 
of the eruption would help us apply these 
findings more accurately. Comparison of 
the characteristics of “elderly” with unex-
plained eczema using CCBs, particularly 
those who recover with CCB withdrawal, 
with those of nonusers ascertained for the 
case–control study would be particularly 
informative.
In case–control studies, selection of 
appropriate controls is often challenging 
and a potential source of bias. Finding 
the “right” controls is particularly diffi-
cult when cases come from a specialized 
population. In this study, cases appear 
to be sicker than controls. Cases used 
more medications than controls, includ-
ing antiarrhythmia agents and nitrates. 
Although the association of these drugs 
with eczema did not reach statistical sig-
nificance, it approached that observed 
with CCBs. These observations raise the 
possibility that either underlying cardiac 
illness or multiple-drug use, rather than 
CCB use alone, may be responsible for 
some cases attributed to CCBs.
In my experience, obtaining and con-
firming data on chronic past drug use is 
very challenging. The steps the investi-
gators took to establish chronic drug use 
were comprehensive and likely to be 
impractical in the United States. A com-
parison of the drugs ascertained through 
each of the three methods used by the 
authors would be instructive. However, 
the prevalence of drug use in the study’s 
controls is consistent with that observed 
in other populations, suggesting that 
controls were well selected and infor-
mational bias was limited (Kaufman et 
al., 2002).
The authors have done an admirable 
job of convincing me that in about half of 
older individuals taking CCBs with new 
onset of an extensive and perhaps pho-
todistributed chronic eczematous erup-
tion not otherwise explained after care-
ful workup, the eruption is due to CCBs. 
How generalizable are these results to 
practice? The data presented suggest that 
CCBs are responsible for only about 15% 
of chronic, otherwise unexplained ecze-
ma in the elderly. The broad net required 
(5 academic centers and 35 practices 
over 2 years) to ascertain 102 cases sug-
gests that unexplained new-onset eczema 
is infrequent in this age group and may be 
even more infrequent in the community 
than in referral and specialist practices.
Given the apparent low prevalence 
of this problem, even among CCB users, 
and the difficulty of performing confirma-
tory studies as good as this one, I do not 
believe that further retrospective studies 
are needed. A further characterization of 
histopathologic characteristics of CCB-
related eruptions may be useful. Although 
better understanding of the mechanism(s) 
of these reactions would be of interest, 
the generalizability of such potential find-
ings to drug-related chronic skin condi-
tions is likely to be limited. Perhaps we 
should declare victory and go home 
knowing that Joly and colleagues’ clinical 
recommendations are sufficiently robust 
to inform practice and remind us that 
chronic as well as short-term use of drugs 
can cause some inflammatory eruptions.
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Differentiation of Postembryonic Skin 
Endothelial Cells
Marvin Karasek1
Specific cell markers for selective isolation and growth of cells from the lym-
phatic and vascular systems have increased our understanding of the structure–
function relationships of both systems. Using these markers, a subset of blood 
vessel endothelial cells (BECs) with the properties of lymphatic endothelial cells 
(LECs) has been identified in psoriasis and eczema. The differentiation potential 
of BECs and LECs in vivo and in vitro is reviewed.
Journal of Investigative Dermatology (2007), 127, 2710–2712. doi:10.1038/sj.jid.5701072
1Department of Dermatology, Stanford University, Stanford, California, USA
Correspondence: Dr Marvin Karasek, Department of Dermatology, Stanford University, 269 Campus 
Drive, CCSR-2, Room 2155, Stanford, California 94305-5168, USA. E-mail: marvek@stanford.edu
Of increasing interest in the pathology 
of inflammatory and fibrotic skin dis-
ease is a role for transformation of both 
blood vessel endothelial cells (BECs) 
and lymphatic endothelial cells (LECs) 
into new cell types. A transition during 
which epithelioid cells lose their polar-
ity and cohesiveness and transform into 
spindle-shaped cells that are more fibro-
blast- or myofibroblast-like is referred to 
